Monoiodinated, Met35-oxidized muscarinic toxin 7 (MT7ox) was synthesized, and its affinity constants for free or N-methyl scopolamine (NMS)-occupied hM 1 receptor were measured directly by equilibrium and kinetic binding experiments. Identical values were obtained with the two types of assay methods, 14 pM and 0.9 nM in free or NMS-liganded receptor states, respectively, highlighting a strong negative cooperativity between this allosteric toxin and NMS. Identical results were obtained with indirect binding experiments with [
brucine, tacrine, staurosporine, and (9S,10S,12R)-2,3,9,10,11-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo [1,2,3-fg:3Ј,2Ј,1Ј-kl] pyrrolo [3,4-i] [1,6]benzodiazocine-10-carboxylic acid hexyl ester (KT5720)] interact allosterically with muscarinic toxin 7. Equilibrium binding experiments with 125 IMT7ox and [
3 H]NMS were conducted to reveal the effects of these ligands on the free receptor, and affinity constants (pK x values) were calculated using the allosteric ternary complex model. Our results suggest that MT7 toxin interacts with hM 1 receptor at a specific allosteric site, which may partially overlap those identified previously for "classic" or "atypical" allosteric agents and highlight the potential of this new allosteric tracer in studying allosterism at muscarinic receptors.
An increasing body of evidence now shows that many Gprotein-coupled receptors are susceptible to allosteric modulation (Christopoulos and Kenakin, 2002) , and this phenomenon is particularly well documented for the five muscarinic acetylcholine receptor subtypes (Tucek and Proska, 1995; Birdsall et al., 1997; Ellis, 1997; Lazareno et al., 2004; Birdsall and Lazareno, 2005) . These receptors are characterized by at least two distinct binding sites. Agonists and competitive antagonists bind to the orthosteric site, located inside the transmembrane domain, whereas allosteric agents induce a positive or a negative alteration of the orthosteric ligand affinity by interacting with an allosteric site, located more extracellularly (Stockton et al., 1983; Ellis et al., 1993; Ellis, 1997; Trankle and Mohr, 1997; Christopoulos et al., 1998; Christopoulos and Kenakin, 2002) . Furthermore, recent publications report the presence of at least two distinct allosteric sites on muscarinic receptors selective for distinct classes of allosteric agents, suggesting that it is possible for three small ligands to bind simultaneously to a muscarinic receptor (Birdsall et al., 2001; Lazareno et al., 2002) . For instance, staurosporine and other indolocarbazole compounds have been shown to interact at a second allosteric site on hM 1 receptor, associated with a positive cooperativity with ACh (Lazareno et al., 2000) .
The effects of allosteric ligands are consistent with a ternary complex model in which the orthosteric and allosteric agents bind simultaneously to the receptor and modify each other's affinities (Stockton et al., 1983; Ehlert, 1988; Lazareno and Birdsall, 1995) . Therefore, the binding and actions of an allosteric ligand with various receptors and orthosteric compounds are defined by two independent parameters, af-finity and cooperativity, which can generate receptor selectivity, which is useful in the context of therapeutic agents (May and Christopoulos, 2003) .
Until now, except for the recently synthesized [ 3 H]dimethyl-W84 used to measure directly the affinities of various allosteric ligands for the M 2 muscarinic receptor (Trankle et al., 1998 (Trankle et al., , 1999 , all pharmacological characterizations of allosteric agents interacting with muscarinic receptors were derived from their indirect effects on the binding of orthosteric ligand such as NMS. Thus, the lack of radiolabeled allosteric ligands selective for the different muscarinic receptor subtypes prevents direct investigation of the interaction of allosteric agents with their specific binding sites.
For instance, approximately 10 different muscarinic toxins have been isolated from the venom of African mambas and, despite a high sequence homology, they exhibit clear differences in their functional activities and possess various profiles of interaction with the five muscarinic receptor subtypes (Bradley, 2000; Karlsson et al., 2000; Onali et al., 2005 (Max et al., 1993; Olianas et al., 2000 Olianas et al., , 2004 Krajewski et al., 2001; Mourier et al., 2003) . However, all of these studies were done indirectly, and the mode of action of this toxin with M 1 receptor is not yet fully understood.
In this article, we first describe the iodination of synthetic MT7ox toxin and the complete physicochemical and pharmacological characterization of the interaction of an oxidized form of monoiodinated toxin with hM 1 receptor in the free and NMS-occupied states. Thus, for the first time, the affinity constants of the MT7ox-hM1 interaction were measured precisely by equilibrium and kinetic experiments using labeled MT7ox as radiotracer. In addition, the negative cooperativity between MT7ox and NMS was evaluated directly by the comparison of the toxin's affinities in the free and liganded receptor states. Furthermore, the effect of various orthosteric and allosteric agents on the dissociation kinetics of 125 I-MT7ox tracers was measured and sheds new light on the mode of interaction of these ligands when this toxin is used as radiotracer. The pharmacological profiles of various ligands were compared using 125 I-MT7ox or [ 3 H]NMS as tracer, and the binding data were analyzed with the allosteric ternary complex model. Finally, the binding of the MT1 toxin to hM 1 receptor was studied using both radiotracers, thereby highlighting the nonidentical pharmacological properties of these two toxins with the same receptor. 
Materials and Methods

Materials
Peptide Synthesis, Disulfide Bond Formation, and Protein Purification
Chemical synthesis, refolding, and purification of the modified toxins were carried out using the methods described previously for the synthesis of the muscarinic MT1 and MT7 toxins (Mourier et al., 2003) . In brief, the toxins were synthesized using the 9-fluorenylmethoxycarbonyl-stepwise solid-phase method with dicyclohexylcarbodiimide/1-hydroxy-7-azabenzotriazole as coupling reagent and Nmethyl pyrrolidone as solvent. After TFA, deprotection, and purification of the crude material, the reduced form of the pure modified synthetic toxins was subjected to an oxidative reaction using a mixture of reduced (GSH) and oxidized (GSSG) glutathione in the presence of guanidine hydrochloride (0.5 M). Finally, the toxins were purified by reversed-phase HPLC using a Vydac C18 column (250 ϫ 10 mm) with a gradient of 40 to 60% of solvent B for 40 min (A, 0.1% TFA in H 2 O; B, 60% acetonitrile and 0.1% TFA in H 2 O) and analytically characterized. Mass determinations were performed on a Micromass Platform II (Micromass, Altrincham, UK).
Preparation of Met35(sulfoxide)MT7 Toxin
MT7ox was obtained by mild oxidation of the MT7 toxin with 0.18% hydrogen peroxide in 0.05 M acetic acid for 15 min at room temperature, and toxin concentration was approximately 0.5 mg/ml (Rusconi and Montecucchi, 1985) . The oxidized derivative was purified by HPLC using an analytical RP-18 (10 ϫ 4.5 cm) HPLC Chromolith-performance column (VWR International, Fontenay sous Bois, France) and elution conditions as described under Radioiodination. The derivative was analytically characterized, and its mass was determined by spectrometric mass analyses.
Radioiodination
Toxins were radioiodinated for 2 min using 0.7 IU of lactoperoxidase (EC 1.11.1.7) from bovine milk using 1 nmol of toxin and 0.5 mCi of carrier-free Na 125 I (PerkinElmer Life and Analytical Sciences, Boston, MA), in 10 l of H 2 O 2 (diluted 1:50,000) and 30 l of 20 mM phosphate buffer, pH 7.2. The monoiodinated toxins were purified using an analytical (10 ϫ 0.45 cm) RP-18 Chromolith-performance column and a 20 to 40% acetonitrile gradient in 30 min (buffer A, aqueous 0.1% TFA; buffer B, 100% acetonitrile and 0.085% TFA) at a flow rate of 2 ml/min. All fractions were collected, and 10 l of each of them was measured with a ␥ counter (1261 Multigamma; LKB Wallac, Little Chalfont, Buckinghamshire, UK). Two fractions containing labeled MT7 toxin were eluted, respectively, at 27 and 29% of acetonitrile. The different iodinated forms of MT7 toxin were isolated and analyzed by binding experiments. The concentration of the radiolabeled toxins was determined according to the specific activity of 125 I corresponding to 2200 dpm/fmol of monoiodotoxin, depending on the age of the radiolabeled toxin and by estimation of its biological activity (usually 80% for 125 I-MT7). The fractions containing pure monoiodinated MT7 were kept at 4°C after the addition of bovine serum albumin (1 mg/ml). A nonradioactive iodination was performed using identical experimental conditions (10 l of a 40 M solution of NaI in 10 M NaOH), then radioiodination, and monoiodinated MT7 toxins were analyzed by mass analysis; the position of the modified residue was then determined by N-terminal protein sequencing.
Mass Analysis and Protein Sequencing
Mass determination was performed on a ESI-Ion Trap Esquire HCT (Bruker Daltonik GmbH, Bremen, Germany) 
CD Analysis
CD spectra were recorded on a Jobin Yvon CD6 spectropolarimeter. Measurements were routinely performed at 20°C in 0.1-cm pathlength quartz cells (Hellma, Plainview, NY) with a peptide concentration of 5.10 Ϫ5 M in 5 mM sodium phosphate buffer, pH 7.4. Spectra were recorded in the 186-to 260-nm wavelength range. Each spectrum represents the average of four spectra.
CHO Cells and Membrane Preparation
Professors P. O. Couraud and A. D. Strosberg (Institut Cochin de Génétique Moléculaire, Paris, France) kindly provided CHO cells stably expressing the cloned human muscarinic M 1 receptor. The cells were grown in plastic Petri dishes (Falcon, Cowley, UK) which were incubated at 37°C in an atmosphere of 5% CO 2 and 95% humidified air in Ham's F-12 medium precomplemented with Lglutamine and bicarbonate (Sigma) supplemented with 10% fetal calf serum and 1% penicillin/streptomycin (Sigma). At 100% confluence, the medium was removed, and the cells were harvested using Versen buffer (PBS ϩ 5 mM EDTA). They were washed with ice-cold phosphate buffer and centrifuged at 1700g for 10 min (4°C). The pellet was suspended in ice-cold buffer (1 mM EDTA, 25 mM sodium phosphate, and 5 mM MgCl 2 , pH 7.4) and homogenized using an Potter-Elvehjem homogenizer (Fisher Scientific Labosi, Elancourt, France). The homogenate was centrifuged at 1700g for 15 min (4°C). The sediment was resuspended in buffer, homogenized, and centrifuged at 1700g for 15 min (4°C). The combined supernatants were centrifuged at 35,000g for 30 min (4°C), and the pellet was suspended in the same buffer (0.1 ml/dish). Protein concentrations were determined according to the Lowry method using bovine serum albumin as standard. The membrane preparations were aliquoted and stored at Ϫ80°C.
I-MT7 Binding Assays
All binding experiments were done at room temperature in 10 mM sodium phosphate, pH 7.2, 135 mM NaCl, 2.5 mM KCl, pH 7.4 (PBS), and 0.1% bovine serum albumin. The reaction was stopped by addition of 2 ϫ 3 ml of ice-cold buffer (PBS) immediately followed by filtration through GF/C glass-fiber filters (Whatman, Clifton, NJ) presoaked in 0.5% polyethylenimine. The bound radioactivity was counted in a ␥ counter (LKB 1261 multigamma). Nonspecific 125 IMT7ox binding was determined in the presence of 100 nM MT7.
Saturation binding assays with unliganded receptor were performed by incubating CHO M 1 membrane (0.2 g of protein/ml) for 18 to 20 h with increasing concentrations of 125 I-MT7ox (1-330 pM). For NMS-occupied receptor binding experiments, CHO M 1 membrane (6.5 g of protein/ml) was first preincubated for 1 h with NMS (1 M) and then for 18 to 20 h with varied concentrations of 125 IMT7ox (40 pM to 2 nM). These NMS-occupied experimental conditions were determined by examining first the residual 125 I-MT7ox specific binding in function of increasing NMS concentrations. NMS concentrations up to 0.1 M were associated with a constant 125 IMT7ox specific binding. At 1 M (10,000 times and 150 times its K d for unliganded and MT7-occupied receptors, respectively), the receptor occupancy by NMS could not be reduced significantly, even with high 125 I-MT7ox concentrations. The association and dissociation kinetic experiments with 125 I-MT7ox were performed on free and NMS-occupied receptors. For both receptor states, the association kinetics were determined using four different concentrations of 125 IMT7ox: 7, 12, 18, and 25 pM for unliganded receptor and 54, 110, 250, and 490 pM for NMS-occupied receptor (means Ϯ S.E.M., n ϭ 3). For dissociation experiments, after an 18-to 20-h preincubation of the free or NMS-occupied receptor with the radioligand, dissociation was monitored after the addition of 100 nM MT7. Aliquots were filtered and counted at different times (means Ϯ S.E.M., n ϭ 6).
To study the effect of various ligands on the dissociation kinetics of 125 I-MT7ox, hM 1 membranes were first preincubated 18 to 20 h with 20 pM 125 I-MT7ox, and then its dissociation was monitored after the addition of saturating concentrations of orthosteric or allosteric compounds (100 times their K dx for free receptor) with 100 nM MT7 toxin. Aliquots were filtered and counted at different times. 125 IMT7ox dissociation data were analyzed assuming a monoexponential decay equation.
The affinities of MT7, MT1 toxins, and various orthosteric and allosteric agents for muscarinic receptors were determined in inhibition binding experiments using 125 I-MT7ox as a tracer. The 125 IMT7ox inhibition assays with free receptors used 15 pM 125 I-MT7ox, 0.2 g of protein/ml, and overnight incubation, whereas 50 pM 125 IMT7ox, 6.5 g of protein/ml, and 6-h incubation were used for NMSoccupied receptors. For NMS-occupied receptor binding experiments, CHO M 1 membrane (6.5 g of protein/ml) was first preincubated for 1 h with NMS (1 M).
Each experiment was done at least three times. For ligands dissolved in DMSO (brucine, staurosporine, and KT5720), we checked that the higher concentration of DMSO present in the binding solution (2%) had no effect on the tracer binding.
[ 3 H]NMS Binding Assays
The effect of MT7 on the equilibrium binding of [ 3 H]NMS was determined in heterologous inhibition experiments. With [ 3 H]NMS as tracer, membrane protein concentrations, adjusted so that no more than 10% of added radioligand was specifically bound (around 1500 -2000 cpm), were incubated in PBS-bovine serum albumin at 25°C for 18 to 22, with varying concentrations of toxin and [
3 H]NMS (0.5 nM) in a final assay volume of 300 l. Nonspecific binding was determined in the presence of 50 M atropine. The reaction was stopped by the addition of 3 ml of ice-cold buffer (PBS) immediately followed by filtration through Whatman GF/C glass-fiber filters presoaked in 0.5% polyethylenimine. The filters were washed once again with 3 ml of ice-cold buffer (PBS), dried, and the bound radioactivity was counted by liquid scintillation spectrometry. Each experiment was done at least three times.
Data Analysis
The binding data from individual experiments (n Ն 3) were analyzed by nonlinear regression analysis using Kaleidagraph 4.0 (Synergy Software, Reading, PA).
Saturation Binding Experiments. The results from saturation binding experiments were subjected to nonlinear regression analysis to obtain the equilibrium dissociation constant (K d ) and the number of binding sites (B max (Cheng and Prusoff, 1973) . K d value of the [ 3 H]NMS on hM 1 receptor was experimentally determined by saturation experiments and was equal to 0.1 nM, as reported previously in the literature (Matsui et al., 1995; Lu et al., 2001) . Likewise, the affinities of the muscarinic toxins in inhibiting the binding of 125 IMT7ox to free or liganded receptors were expressed as pK i values.
The allosteric ternary complex model (Ehlert, 1988) was used to analyze the data on the effect of orthosteric and allosteric agents on the specific binding of the allosteric radioligand 125 I-MT7ox and of the allosteric agents on the specific binding of the orthosteric radioligand [
3 H]NMS. We used the following equation : ing of L in the absence of X. K L and K x are the affinity constants for the binding of L and X, respectively, to the unliganded receptors. ␣ Denotes the cooperative factor for the allosteric interaction between X and L (with ␣ Ͼ 1, ␣ Ͻ 1, ␣ ϭ 1 indicating positive, negative, and neutral cooperativity, respectively). n H represents the slope factor of the curve. The positive cooperativity of KT5720 with 125 I-MT7ox may be associated, at high KT5720 concentration, with slow kinetics of 125 IMT7ox binding that prevents equilibrium from being reached. In that case, the binding data were better fitted with the following equation, which assumes that the modulator completely prevents the dissociation of radioligand from the receptor Lazareno et al., 2000) :
where B LXt is the observed specific binding under nonequilibrium conditions, B LX is the predicted equilibrium binding defined in eq. 1, t is the incubation time, and k off is the dissociation rate constant of 125 I-MT7ox.
Results
Chemical Synthesis, Refolding, Purification, and CD Spectra Analyses of Wild-Type and Modified MT7 Toxins. The one-step, solid-phase chemical syntheses of the natural and modified MT7 toxins were performed using a program developed previously for the synthesis of nicotinic and muscarinic toxins (Mourier et al., 2000 (Mourier et al., , 2003 . For each toxin, the synthesis proceeded smoothly, and the final TFA cleavage yielded a crude mixture in which the main component, corresponding to the reduced form of each protein, constituted 30 to 40% of the total reaction mixture analyzed by reversed-phase HPLC. Refolding of these toxins was performed in the presence of reduced and oxidized glutathione and 0.5 M guanidine hydrochloride, and the final oxidation yield was approximately 30%. The refolded modified synthetic MT7 toxins were purified to homogeneity on a C18 reversed-phase HPLC column. The purity and identity of the toxins was confirmed by electrospray mass analysis. Finally, the CD spectra of the different synthetic toxins were recorded and displayed a typical ␤-sheet signature with pronounced maxima and minima at 194 to 196 and 210 to 216 nm, respectively (data not shown) as described previously (Mourier et al., 2003) .
Iodination of MT7 Toxin and Kinetic Binding Experiments of Labeled Derivatives. To obtain a high specificactivity ligand that interacts with the allosteric site of the hM 1 receptor, MT7 toxin was monoiodinated under mild conditions using the lactoperoxidase method and a 1:5 Na 125 I/ protein ratio (as described under Materials and Methods). After the reaction, the resulting products were separated by C18 reversed-phase HPLC chromatography (Fig. 1) . As shown in Fig. 1A , the chromatogram displays the presence of a major peak at a retention time (RT) of 13.2 min corresponding to the unmodified MT7 toxin (experimental mass, 7472.9) and three minor peaks: a, RT, 10.9 min; mass, 7488.4 (ϩ15.5); b, RT, 12.2 min; mass, 7614.2 (ϩ141.3); and c, RT, 14.3 min; mass, 7598.6(ϩ125.7), corresponding, respectively, to an oxidized form of the MT7 toxin (peak a), its monoiodinated derivative (peak b), and the monoiodinated derivative of the wild-type MT7 toxin (peak c). According to the mild oxidative conditions used for the toxin iodination, the only residue likely to be oxidized is the sole methionine at position 35. To confirm the location of this oxidation, the same oxidative conditions were applied to an M35A modified toxin, which was unchanged by this treatment (data not shown). Thus, a Met35-sulfoxide derivative of the MT7 toxin was synthesized (as described under Materials and Methods), analyzed by mass spectrometry, and submitted to nonradioactive iodination. As shown in Fig. 1B , the HPLC profile obtained after nonradioactive iodination of MT7ox presents a major peak with a mass and an RT identical with that of peak a, corresponding to the unmodified MT7ox and a minor peak with a mass and an RT identical with those of peak b identified as a monoiodinated MT7ox toxin. After radioiodination of the wild-type toxin, the radioactivity was found for the most part in peak c (80%) and also in peak b (15%) (Fig. 1AЈ) . MT7ox toxin was radioiodinated, and the radioactivity was entirely associated with the fraction at the RT of 12.2 min corresponding to the monoiodinated MT7ox toxin (called 125 IMT7ox) (Fig. 1BЈ) . Finally, the analysis of the first 40 cycles of the N-terminal protein sequencing of monoiodinated MT7 toxin indicated no modification at Tyr30 and Tyr36, assuming, in the absence of histidine residue, that iodination occurred on the third and last tyrosine residue in position 51. Dissociation kinetic experiments were performed first with the two radioiodinated MT7 peaks b and c using a free CHO hM 1 membrane preparation. As reported in Fig. 2A , a large fraction of peak c bound stably to the receptor. After more than 2 days of incubation, a large excess of nonradioactive MT7 displaced less than 40% of the labeled toxin. In contrast, dissociation of 125 I-MT7ox peak b from the receptor was complete and displayed a monoexponential relationship with a dissociation rate constant (k off ) of 3.3 Ϯ 0.2 10 Ϫ3 ⅐ min Ϫ1 . Thus, all of the following experiments with labeled toxin were performed using the reversible peak b as tracer ( 125 I- MT7ox). The association rate constant (k on ) of this compound was determined using a constant concentration of membrane preparation and four different concentrations of the 125 IMT7ox (Fig. 2B) . The k on value calculated from the linearization plot of K app versus the 125 I-MT7ox concentrations (Fig. 2B, inset) Kinetic and saturation experiments were also performed with the NMS-occupied receptor, obtained after 1 h of preincubation of the CHO hM 1 membrane preparation with a large excess of NMS (1 M). Association and dissociation constants calculated from their respective kinetic experiments (Fig. 4, A and B To complete the direct characterization of the MT7-hM1 interaction, competitive binding experiments on 125 I-MT7ox and wild-type MT7 with free and NMS-occupied receptor were performed. Figure 6 shows the two inhibition binding curves obtained with, in both cases, a complete displacement of the tracer by the MT7 toxin. The affinity constants (K i ) deduced from these competition binding curves using the Cheng-Prusoff equation of 11.6 Ϯ 1.5 pM (pK i ϭ 10.95 Ϯ 0.01) and 1.7 Ϯ 0.2 nM (pK i ϭ 8.75 Ϯ 0.05) for the free and NMS-occupied receptor, respectively, are very similar to those determined from saturation or kinetic experiments. In addition, 125 I-MT7ox binding was inhibited with the nonradioactive iodinated oxidized toxin, and the calculated K i constants with free or NMS-occupied receptors are similar to those obtained with the wild-type MT7 of 18.62 Ϯ 0.35 pM (pK i ϭ 10.73 Ϯ 0.13) and 2.72 Ϯ 0.12 nM (pK i ϭ 8.57 Ϯ 0.02), respectively (data not shown). 125 I-MT7ox-hM 1 binding, the effect of these various ligands on MT7-induced 125 IMT7ox dissociation was investigated. As shown in Fig. 7 , the test compounds induce different types of effects on 125 IMT7ox dissociation. First, KT5720 slows down the dissociation kinetics weakly but significantly (Table 1) , whereas atropine, NMS, staurosporine, and mostly gallamine, brucine, and tacrine increase the 125 I-MT7ox dissociation rate constants from 2-to 100-fold (Table 1) . For example, tacrine induces a complete 125 I-MT7ox dissociation in a few minutes compared with the t 1/2 dissociation of 3.5 h obtained with MT7 toxin alone. Thus, because modification of radioligand dissociation by a test compound demonstrates its allosteric behavior, all of the ligands studied can be considered allosteric modulators of the 125 I-MT7ox-hM 1 interaction. In contrast, MT1 toxin does not affect the MT7 dissociation rate (Fig. 7) , suggesting a competitive interaction between the two toxins even if a high negative cooperativity could not be excluded.
Inhibition of 125 I-MT7ox Binding to Free hM 1 Receptor by Various Allosteric and Orthosteric Ligands. Specific 125 I-MT7ox binding to free receptor was inhibited by increasing concentrations of various ligands as the orthosteric antagonists, NMS and atropine, or the allosteric agents gallamine, brucine, tacrine, staurosporine, and KT5720 (Fig.  8A) . At the higher concentrations of NMS and atropine, the 125 I-MT7ox binding was not completely abolished, indicating a negative cooperative interaction of these antagonists with the allosteric tracer. According to the ternary complex model, if such cooperative interaction occurred, the derived affinity constants for the unliganded receptor should match those obtained in inhibition binding experiments with [
3 H]NMS. The slope factors measured in these experiments are not significantly different from the unity, and the affinity constants of these two ligands are in the subnanomolar range (Table 2) . For the allosteric agents, a complete radiotracer displacement was observed with brucine, tacrine, and staurosporine but not with gallamine, whereas with KT5720, the 125 I-MT7ox binding first increased by 35% at 6 M and then decreased at higher concentrations (Fig. 8A) . The KT5720 complex binding curve may reflect a kinetic artifact of high concentrations of this agent on the 125 I-MT7ox binding and was fitted according to a kinetic ternary complex equation (see eq. 2 under Materials and Methods). Depending on the allosteric properties of these agents observed in 125 I-MT7ox dissociation experiments, their affinity constants (log Kx ϭ ϪpK x ) reported in Table 2 were derived from the treatment of the inhibition binding curves with the ternary complex equation. All of these ligands are characterized by affinity constants in the micromolar range (Table 2) .
In equilibrium binding experiments with MT1 toxin, 125 IMT7ox binding to free M 1 receptor was completely inhibited by MT1 (Fig. 8B ) and associated with a pK i ϭ 7.58 Ϯ 0.03 obtained by competitive treatment of the binding curve using the Cheng-Prusoff equation. Thus, MT1 interacts with the hM 1 receptor with an affinity 3 orders of magnitude lower than that of MT7 (Table 2) (Fig. 9A) . Table  2 gives the affinity constants (log Kx ϭ ϪpK x ) for the interaction of these allosteric ligands with unliganded receptor and the cooperativity factors associated with the quantitative analysis of these interactions according to the ternary complex model (eq. 1).
The effects of orthosteric ligands, such as NMS and atropine, on [ 3 H]NMS binding are illustrated in Fig. 9B , and the equilibrium binding parameters are reported in Table 2 . The pK i (Ϫlog K i ) constants from these competition experiments were calculated from their IC 50 values by applying the Cheng-Prusoff equation. The slopes of these curves did not deviate from unity. In view of the lack of effect of the MT1 toxin, in our experimental conditions, on the [ 3 H]NMS dissociation kinetics (Mourier et al., 2003) , its competitive binding curve was treated as for classic orthosteric ligands (Table 2) .
Discussion
With the exception of the [ 3 H]dimethyl-W84 radiotracer, which binds to the allosteric site on the hM 2 receptor and has recently been used to characterize the interaction of various ligands with this receptor subtype , all of the interactions of allosteric agents with muscarinic receptors have been inferred from their indirect effects on the kinetics or equilibrium binding of orthosteric radioligands, principally [
3 H]NMS. Thus, to characterize directly the interaction of the hM1 receptor with selective allosteric MT7 toxin, we radioiodinated this toxin in select conditions that generate a high-affinity iodinated toxin that binds reversibly and characterized it pharmacologically. Furthermore, this allosteric radiotracer was used to determine the binding constants of various orthosteric and allosteric ligands, allowing a comparison with results previously obtained using
The enzymatic radioiodination of MT7 and the mild oxidative conditions used in this labeling process generate two MT7 toxins derivatives, monoiodinated on Tyr51 and with or without a sulfoxidation on Met35 residue. The dissociation kinetics of these two molecules have been performed, and their profiles differ widely. Thus, the monoiodinated MT7 binds quasi-irreversibly on the hM 1 receptor, whereas the dissociation of the 125 I-MT7ox displays a monoexponential relationship with a complete dissociation at equilibrium ( Fig.  2A) . These results confirm the huge stability of the MT7-hM 1 interaction, as it was identified previously with [ 3 H]NMS binding (Max et al., 1993; Olianas et al., 2000; Krajewski et al., 2001; Mourier et al., 2003) , and suggest that the oxidation of the Met35 significantly destabilizes this interaction. This property was confirmed by studying the stability of the toxin-receptor complexes, evaluated by the [ 3 H]NMS association kinetic performed after toxin preincubation. In these experiments, wild-type MT7 completely blocks the [ 3 H]NMS binding, whereas preincubation with MT7ox allows efficient binding of [ 3 H]NMS (in 2 h, 60% of the binding control level, data not shown). Furthermore, the alteration of the stability of the MT7-hM 1 interaction, without a significant effect on the apparent toxin affinity constant, has been observed previously with the F38I mutant (Krajewski et al., 2001) .
Thus, 125 I-MT7ox toxin interacts reversibly with the hM 1 receptor and was used as radiotracer in association/dissociation, saturation, and competition experiments to fully characterize the interaction of MT7ox toxin with free and NMSoccupied hM 1 receptor.
The affinity constants of 125 I-MT7ox toxin, obtained from kinetic experiments, are equal to 13.20 Ϯ 2.3 pM and 0.79 Ϯ 0.17 nM with unliganded and NMS-occupied receptor, respectively. Thus, the calculated cooperative factor is 0.016. With saturation experiments, similar values of 14.26 Ϯ 3.13 pM and 0.92 Ϯ 0.02 nM were obtained, respectively, associated with a cooperative factor of 0.015. The number of toxin binding sites calculated from saturation experiments is 15.1 Ϯ 2.8 pmol/mg of protein and 10.6 Ϯ 1.4 pmol/mg of protein in free and liganded receptor states, respectively. In NMS-occupied receptor, this value is probably underestimated because of the impossibility of totally saturating the receptor in these experimental conditions. In competition binding experiments using monoiodinated MT7ox as tracer, inhibition constants of wild-type MT7 toxin with free and NMS-occupied receptor were, respectively, 11.6 Ϯ 1.5 pM (pK i ϭ 10.95 Ϯ 0.01) and 1.7 Ϯ 0.2 nM (pK i occ ϭ 8.75 Ϯ 0.05), confirming the huge negative allosteric effect of NMS on 125 I-MT7ox binding. This effect was mainly supported by a dramatic increase in 125 I-MT7ox dissociation in the NMSoccupied receptor (t 1/2 ϭ 5 min) compared with the unliganded receptor (t 1/2 ϭ 3.5h) ( Figs. 2A and 4A) , with the association kinetics being highly similar (Figs. 2B and 4B) . Furthermore, a similar negative cooperativity (␣ ϭ 0.014) between NMS and MT7 was calculated when [ 3 H]NMS was used as tracer and the inhibition binding curves were treated with the ternary complex eq. 1 (Table 2 ). In this model, the affinity of the MT7 for the free receptor is 29 Ϯ 3 pM (pK x ϭ 10.53 Ϯ 0.08) similar to that obtained from 125 I-MT7ox competition experiment (Table 2) . Furthermore, the affinity of the MT7 for the NMS-occupied receptor can be calculated as log(␣ ⅐ Kx) ϭ ϪpK x occ ϭ 8.67, and this value agrees well with the experimental affinity of the MT7 for the NMS-occupied receptor measured previously with single-time point experiments (pK i occ ϭ Ϫlog IC 50 diss ϭ 8.60 Ϯ 0.04) (Mourier et al., 2003) . Thus, the similarity of the binding constants and cooperativity factors of the MT7-hM 1 receptor interaction measured directly using 125 I-MT7ox or indirectly with Lazareno et al. (1998) . b Data from Lazareno et al. (2000) .
Allosteric Interaction at M 1 Receptor Using 125 I-MT7ox
